CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Association of Cardiovascular Disease With Respiratory Disease Is Cardiac Diastolic Dysfunction a Part of Post-Menopausal Syndrome? Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors Heart Failure With Improved Ejection Fraction-Is it Possible to Escape One’s Past? Percutaneous Atriotomy for Levoatrial–to–Coronary Sinus Shunting in Symptomatic Heart Failure: First-in-Human Experience A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)

Review Article2017 Nov;5(11):763-771.

JOURNAL:JACC Heart Fail. Article Link

Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions

Hsu JJ, Ziaeian B, Fonarow GC. Keywords: HFbEF; HFmrEF; HFpEF; epidemiology; heart failure with borderline ejection fraction; heart failure with mid-range ejection fraction; heart failure with preserved ejection fraction; outcomes

FULL TEXT PDF